Janney Montgomery Scott LLC trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 12.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,935 shares of the company's stock after selling 6,657 shares during the period. Janney Montgomery Scott LLC owned about 0.16% of Krystal Biotech worth $8,282,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in KRYS. Fifth Third Bancorp grew its stake in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Krystal Biotech in the 4th quarter worth about $95,000. Covestor Ltd grew its stake in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares in the last quarter. GAMMA Investing LLC grew its stake in Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares in the last quarter. Finally, US Bancorp DE grew its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on KRYS shares. Citigroup lowered their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. Guggenheim lowered their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 6th. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday, May 7th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $211.13.
View Our Latest Research Report on Krystal Biotech
Krystal Biotech Stock Performance
NASDAQ:KRYS traded up $0.37 during midday trading on Friday, reaching $132.46. 691,210 shares of the stock traded hands, compared to its average volume of 286,027. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $219.34. The business has a 50-day moving average of $143.35 and a two-hundred day moving average of $159.15. The stock has a market capitalization of $3.83 billion, a PE ratio of 31.84 and a beta of 0.65.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. Research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Krystal Biotech Company Profile
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
